Carruthers R. Michael, CFO of Edgewise Therapeutics ($EWTX), made two open market sales totaling about $41,000 over the past year, with the latest on August 12, 2025. These rank 10,587th among 11,678 insiders, well below the average sale of $8.6 million across 6.4 transactions. No open market purchases recorded.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | A | Stock Option (Right to Buy) | 161250 | $0.00 | 161,250.0000 | 104,940,493 | 9999.99% | 0.15% |
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | M | Common Stock | 5781 | $0.00 | 87,590.0000 | 104,940,493 | 7.07% | 0.01% |
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | S | Common Stock | 1428 | $13.39 | 86,162.0000 | 104,940,493 | 1.63% | 0.00% |
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | M | Restricted Stock Units | 5781 | $0.00 | 17,344.0000 | 104,940,493 | 25.00% | 0.01% |
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | A | Restricted Stock Units | 26875 | $0.00 | 26,875.0000 | 104,940,493 | 9999.99% | 0.03% |
| July 23, 2025 | Elevation Oncology, Inc. | $ELEV | Carruthers R Michael | Not found | D | Stock Option (Right to Buy) | 47330 | $0.00 | 0.0000 | 59,173,854 | 100.00% | 0.08% |
| July 23, 2025 | Elevation Oncology, Inc. | $ELEV | Carruthers R Michael | Not found | D | Stock Option (Right to Buy) | 15619 | $0.00 | 0.0000 | 59,173,854 | 100.00% | 0.03% |
| July 23, 2025 | Elevation Oncology, Inc. | $ELEV | Carruthers R Michael | Not found | D | Stock Option (Right to Buy) | 31238 | $0.00 | 0.0000 | 59,173,854 | 100.00% | 0.05% |
| July 23, 2025 | Elevation Oncology, Inc. | $ELEV | Carruthers R Michael | Not found | D | Stock Option (Right to Buy) | 35000 | $0.00 | 0.0000 | 59,173,854 | 100.00% | 0.06% |
| July 23, 2025 | Elevation Oncology, Inc. | $ELEV | Carruthers R Michael | Not found | D | Stock Option (Right to Buy) | 35000 | $0.00 | 0.0000 | 59,173,854 | 100.00% | 0.06% |
| June 5, 2025 | Elevation Oncology, Inc. | $ELEV | Carruthers R Michael | Not found | A | Stock Option (Right to Buy) | 35000 | $0.00 | 35,000.0000 | 59,173,854 | 9999.99% | 0.06% |
| May 28, 2025 | OnKure Therapeutics, Inc. | $OKUR | Carruthers R Michael | Not found | A | Stock Option (right to buy) | 7650 | $0.00 | 7,650.0000 | 3,447,071 | 9999.99% | 0.22% |
| May 1, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | M | Common Stock | 5209 | $0.00 | 82,328.0000 | 95,130,053 | 6.75% | 0.01% |
| May 2, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | S | Common Stock | 1314 | $16.45 | 81,014.0000 | 95,130,053 | 1.60% | 0.00% |
| May 1, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | M | Restricted Stock Units | 5209 | $0.00 | 0.0000 | 95,130,053 | 100.00% | 0.01% |
| Oct. 11, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | M | Common Stock | 70000 | $0.71 | 76,904.0000 | 93,813,346 | 1013.91% | 0.07% |
| Oct. 11, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | M | Stock Option (Right to Buy) | 70000 | $0.00 | 127,122.0000 | 93,813,346 | 35.51% | 0.07% |
| Oct. 4, 2024 | OnKure Therapeutics, Inc. | $OKUR | Carruthers R Michael | Not found | A | Stock Option (right to buy) | 15300 | $0.00 | 15,300.0000 | 316,142 | 9999.99% | 4.84% |
| Oct. 4, 2024 | OnKure Therapeutics, Inc. | $OKUR | Carruthers R Michael | Not found | A | Class A Common Stock | 874 | $0.00 | 874.0000 | 316,142 | 9999.99% | 0.28% |
| Oct. 4, 2024 | OnKure Therapeutics, Inc. | $OKUR | Carruthers R Michael | Not found | A | Class A Common Stock | 4065 | $0.00 | 4,939.0000 | 316,142 | 465.10% | 1.29% |
| Oct. 4, 2024 | OnKure Therapeutics, Inc. | $OKUR | Carruthers R Michael | Not found | A | Stock Option (right to buy) | 1760 | $0.00 | 1,760.0000 | 316,142 | 9999.99% | 0.56% |
| Oct. 4, 2024 | OnKure Therapeutics, Inc. | $OKUR | Carruthers R Michael | Not found | A | Stock Option (right to buy) | 1324 | $0.00 | 1,324.0000 | 316,142 | 9999.99% | 0.42% |
| Sept. 20, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | S | Common Stock | 50000 | $28.55 | 6,904.0000 | 93,515,356 | 87.87% | 0.05% |
| Sept. 20, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | M | Stock Option (Right to Buy) | 96068 | $0.00 | 40,990.0000 | 93,515,356 | 70.09% | 0.10% |
| Sept. 20, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | M | Common Stock | 46068 | $1.93 | 81,996.0000 | 93,515,356 | 128.22% | 0.05% |
| Sept. 20, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | S | Common Stock | 46068 | $28.59 | 35,928.0000 | 93,515,356 | 56.18% | 0.05% |
| Sept. 20, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | S | Common Stock | 4064 | $28.59 | 31,864.0000 | 93,515,356 | 11.31% | 0.00% |
| Sept. 20, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | S | Common Stock | 24960 | $28.59 | 6,904.0000 | 93,515,356 | 78.33% | 0.03% |
| Sept. 20, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | M | Common Stock | 50000 | $1.93 | 56,904.0000 | 93,515,356 | 724.22% | 0.05% |
| Aug. 12, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | A | Restricted Stock Units | 23125 | $0.00 | 23,125.0000 | 93,515,356 | 9999.99% | 0.02% |
| Aug. 12, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | A | Stock Option (Right to Buy) | 138750 | $0.00 | 138,750.0000 | 93,515,356 | 9999.99% | 0.15% |
| June 13, 2024 | Elevation Oncology, Inc. | $ELEV | Carruthers R Michael | Not found | A | Stock Option (Right to Buy) | 35000 | $0.00 | 35,000.0000 | 51,811,882 | 9999.99% | 0.07% |
| May 1, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | M | Restricted Stock Units | 5208 | $0.00 | 5,209.0000 | 87,567,307 | 50.00% | 0.01% |
| May 1, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | M | Common Stock | 5208 | $0.00 | 37,387.0000 | 87,567,307 | 16.18% | 0.01% |
| May 2, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | S | Common Stock | 2157 | $18.91 | 35,230.0000 | 87,567,307 | 5.77% | 0.00% |
| Jan. 23, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | M | Common Stock | 90000 | $1.93 | 119,024.0000 | 63,723,600 | 310.09% | 0.14% |
| Jan. 23, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | M | Stock Option (Right to Buy) | 90000 | $0.00 | 137,058.0000 | 63,723,600 | 39.64% | 0.14% |
| Jan. 23, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Carruthers R Michael | Chief Financial Officer | S | Common Stock | 90000 | $15.78 | 29,024.0000 | 63,723,600 | 75.62% | 0.14% |